Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Petrobras Brasileiro A Dynamic Market Landscape

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
Energy Company Market Capitalization
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

On March 12, 2024, analyst Bruno Amorim from Goldman Sachs reiterated a Buy rating on Petrobras Brasileiro (NYSE:PBR) while adjusting the price target from $19.7 to $17.6. This update follows a previous upgrade from Neutral to Buy and a price target increase from $13 to $18.1. Conversely, B of A Securities has set a new price target of $16.00 for Petrobras Brasileiro, anticipating a potential 7.45% upside in the next 12 months. The fluctuating analyst ratings and recommendations for Petrobras Brasileiro underscore the ever-changing landscape of stock analysis and market conditions.

Petrobras (PBR) Stock Sees Slight Increase, But Long-Term Growth Uncertain

On March 12, 2024, Petrobras (PBR) saw a slight increase in its stock performance. The stock opened at $14.83, which was $0.27 higher than its previous close. Throughout the trading day, PBR shares increased by $0.25, resulting in a 1.72% rise in its price. Despite this positive movement, PBR is currently trading in the middle of its 52-week range and below its 200-day simple moving average. This indicates that the stock may not be experiencing significant upward momentum in the long term. Investors may want to consider these factors when evaluating PBR as a potential investment. While the short-term price increase is a positive sign, the overall trend of the stock suggests that it may not be experiencing strong growth. It is important for investors to conduct thorough research and analysis before making any investment decisions. By considering the price momentum and overall performance of PBR, investors can make informed choices about whether or not to include this stock in their portfolio.

PBR Stock Performance on March 12, 2024: Revenue, Net Income, and EPS Decline

On March 12, 2024, investors were closely watching the performance of PBR stock after the company released its financial results. According to data from CNN Money, PBR reported a total revenue of $102.50 billion for the past year, with $27.09 billion in revenue for the fourth quarter. Similarly, PBR’s net income for the past year was reported at $24.95 billion, with $6.26 billion in net income for the fourth quarter. Earnings per share (EPS) for PBR were reported at $3.83 for the past year and $0.97 for the fourth quarter. Overall, PBR’s financial performance on March 12, 2024, showed a decline in total revenue, net income, and earnings per share compared to the previous year. However, the company managed to maintain its performance from the previous quarter, which may have been seen as a positive sign by investors. Investors and analysts will continue to monitor PBR’s financial performance in the coming quarters to see if the company can reverse the downward trend in revenue, net income, and earnings per share. The stock performance on March 12, 2024, may have reflected investor sentiment towards PBR’s financial results and future outlook.

Tags: PBR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Mining technology

MicroCloud Hologram Shares Surge After Trading Resumes

Biotechnology Stock Exchange

Analysts Bullish on Alpine Immune Sciences Price Targets and Ratings Upgraded

Finance_Commercial (2)

Reminder WT Offshore ExDividend Date Approaching

Recommended

Jakks Pacific Reports Disappointing Q4 2023 Earnings

2 years ago
Ecommerce Stock Exchange

Notable Options Market Activity for Shopify

2 years ago
Fannie Mae Stock

Fannie Mae’s Public Offering Plans Derailed by Prominent Investor

3 months ago
Ocugen Stock

Ocugen Shares Face Critical Test Amid Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

by Rodolfo Hanigan
February 7, 2026
0

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The...

Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves
  • Deluxe Stock Gains Momentum on Successful Fintech Transition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com